Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Analysis of circulating soluble programmed death 1 (PD-1), neuropilin 1 (NRP-1) and human leukocyte antigen-G (HLA-G) in psoriatic patients.

Bartosińska J, Michalak-Stoma A, Kowal M, Raczkiewicz D, Krasowska D, Chodorowska G, Giannopoulos K.

Postepy Dermatol Alergol. 2019 Apr;36(2):167-172. doi: 10.5114/ada.2018.73329. Epub 2018 Feb 5.

2.

Efficacy of daratumumab monotherapy in real-world heavily pretreated patients with relapsed or refractory multiple myeloma.

Salomon-Perzyński A, Walter-Croneck A, Usnarska-Zubkiewicz L, Dytfeld D, Zielińska P, Wojciechowska M, Hołojda J, Robak P, Pasternak A, Knopińska-Posłuszny W, Hawrylecka D, Wójtowicz M, Szeremet A, Osowiecki M, Mordak-Domagała M, Zaucha JM, Giannopoulos K, Warzocha K, Jamroziak K.

Adv Med Sci. 2019 Sep;64(2):349-355. doi: 10.1016/j.advms.2019.05.001. Epub 2019 May 21.

PMID:
31125864
3.

Targeting Immune Signaling Checkpoints in Acute Myeloid Leukemia.

Giannopoulos K.

J Clin Med. 2019 Feb 12;8(2). pii: E236. doi: 10.3390/jcm8020236. Review.

4.

Decreased blood CD4+PD-1+ and CD8+PD-1+ T cells in psoriatic patients with and without arthritis.

Bartosińska J, Zakrzewska E, Purkot J, Michalak-Stoma A, Kowal M, Krasowska D, Chodorowska G, Giannopoulos K.

Postepy Dermatol Alergol. 2018 Aug;35(4):344-350. doi: 10.5114/ada.2018.75609. Epub 2018 Aug 21.

5.

Inhibition of protein disulfide isomerase induces differentiation of acute myeloid leukemia cells.

Chlebowska-Tuz J, Sokolowska O, Gaj P, Lazniewski M, Firczuk M, Borowiec K, Sas-Nowosielska H, Bajor M, Malinowska A, Muchowicz A, Ramji K, Stawinski P, Sobczak M, Pilch Z, Rodziewicz-Lurzynska A, Zajac M, Giannopoulos K, Juszczynski P, Basak GW, Plewczynski D, Ploski R, Golab J, Nowis D.

Haematologica. 2018 Nov;103(11):1843-1852. doi: 10.3324/haematol.2018.190231. Epub 2018 Jul 12.

6.

The expression of selected molecular markers of immune tolerance in psoriatic patients.

Bartosińska J, Purkot J, Kowal M, Michalak-Stoma A, Krasowska D, Chodorowska G, Giannopoulos K.

Adv Clin Exp Med. 2018 Jun;27(6):721-725. doi: 10.17219/acem/78020.

7.

DNA methylation signature in blood does not predict calendar age in patients with chronic lymphocytic leukemia but may alert to the presence of disease.

Spólnicka M, Zbieć-Piekarska R, Karp M, Machnicki MM, Własiuk P, Makowska Ż, Pięta A, Gambin T, Gasperowicz P, Branicki W, Giannopoulos K, Stokłosa T, Płoski R.

Forensic Sci Int Genet. 2018 May;34:e15-e17. doi: 10.1016/j.fsigen.2018.02.004. Epub 2018 Feb 7. No abstract available.

PMID:
29472117
8.

Optogenetics in cancer drug discovery.

Kiełbus M, Czapiński J, Odrzywolski A, Stasiak G, Szymańska K, Kałafut J, Kos M, Giannopoulos K, Stepulak A, Rivero-Müller A.

Expert Opin Drug Discov. 2018 May;13(5):459-472. doi: 10.1080/17460441.2018.1437138. Epub 2018 Feb 15. Review.

PMID:
29447015
9.

Expression of CD274 (PD-L1) is associated with unfavourable recurrent mutations in AML.

Zajac M, Zaleska J, Dolnik A, Bullinger L, Giannopoulos K.

Br J Haematol. 2018 Dec;183(5):822-825. doi: 10.1111/bjh.15040. Epub 2017 Dec 19. No abstract available.

PMID:
29265177
10.

Analysis of NPM1 splice variants reveals differential expression patterns of prognostic value in acute myeloid leukemia.

Zajac M, Dolnik A, Stasiak G, Zaleska J, Kielbus M, Czapinski J, Schunn M, Correa SC, Glodkowska-Mrowka E, Sundaram RC, Jankowska-Lecka O, Schlenk RF, Döhner H, Döhner K, Stepulak A, Bullinger L, Giannopoulos K.

Oncotarget. 2017 Aug 3;8(56):95163-95175. doi: 10.18632/oncotarget.19871. eCollection 2017 Nov 10.

11.

Suppressed Programmed Death 1 Expression on CD4+ and CD8+ T Cells in Psoriatic Patients.

Bartosińska J, Zakrzewska E, Raczkiewicz D, Purkot J, Michalak-Stoma A, Kowal M, Krasowska D, Chodorowska G, Giannopoulos K.

Mediators Inflamm. 2017;2017:5385102. doi: 10.1155/2017/5385102. Epub 2017 Oct 17.

12.

Differential expression of programmed death 1 (PD-1) on CD4+ and CD8+ T cells in rheumatoid arthritis and psoriatic arthritis.

Bartosińska J, Zakrzewska E, Król A, Raczkiewicz D, Purkot J, Majdan M, Krasowska D, Chodorowska G, Giannopoulos K.

Pol Arch Intern Med. 2017 Dec 22;127(12):815-822. doi: 10.20452/pamw.4137. Epub 2017 Nov 3.

13.

Novel prognostic molecular factors: a quantum leap in the field of chronic lymphocytic leukemia.

Zakrzewska E, Pirog M, Purkot J, Giannopoulos K.

Folia Histochem Cytobiol. 2017;55(3):95-106. doi: 10.5603/FHC.a2017.0019. Epub 2017 Oct 10. Review.

14.

HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies.

Bobrowicz M, Dwojak M, Pyrzynska B, Stachura J, Muchowicz A, Berthel E, Dalla-Venezia N, Kozikowski M, Siernicka M, Miazek N, Zapala P, Domagala A, Bojarczuk K, Malenda A, Barankiewicz J, Graczyk-Jarzynka A, Zagozdzon A, Gabrysiak M, Diaz JJ, Karp M, Lech-Maranda E, Firczuk M, Giannopoulos K, Efremov DG, Laurenti L, Baatout D, Frenzel L, Malinowska A, Slabicki M, Zenz T, Zerrouqi A, Golab J, Winiarska M.

Blood. 2017 Oct 5;130(14):1628-1638. doi: 10.1182/blood-2016-08-736066. Epub 2017 Aug 22.

PMID:
28830887
15.

Prognostic impact of NOTCH1, MYD88, and SF3B1 mutations in Polish patients with chronic lymphocytic leukemia.

Putowski M, Podgórniak M, Piróg M, Knap J, Zaleska J, Purkot J, Zawiślak J, Zakrzewska E, Karczmarczyk A, Własiuk P, Subocz E, Giannopoulos K.

Pol Arch Intern Med. 2017 Apr 28;127(4):238-244. doi: 10.20452/pamw.3998. Epub 2017 Apr 20.

16.

A multicenter prospective study on efficacy and safety of imatinib generics: A report from Polish Adult Leukemia Group imatinib generics registry.

Sacha T, Góra-Tybor J, Szarejko M, Bober G, Grzybowska-Izydorczyk O, Niesiobędzka-Krężel J, Dudziński M, Wasilewska E, Myśliwiec K, Gil J, Gniot M, Pietkun I, Mędraś E, Hołojda J, Wącław J, Giannopoulos K.

Am J Hematol. 2017 Jul;92(7):E125-E128. doi: 10.1002/ajh.24748. Epub 2017 May 26. No abstract available.

17.

Efficacy and toxicity of compassionate ibrutinib use in relapsed/refractory chronic lymphocytic leukemia in Poland: analysis of the Polish Adult Leukemia Group (PALG).

Iskierka-Jażdżewska E, Hus M, Giannopoulos K, Mądro E, Hołojda J, Piotrowska M, Zaucha JM, Piszczek W, Szeremet A, Wojciechowska M, Steckiewicz P, Knopińska-Posłuszny W, Osowiecki M, Drozd-Sokołowska J, Kumiega B, Kyrcz-Krzemień S, Hałka J, Dudziński M, Wieszczy P, Robak T, Warzocha K, Jamroziak K.

Leuk Lymphoma. 2017 Oct;58(10):2485-2488. doi: 10.1080/10428194.2017.1292353. Epub 2017 Feb 28. No abstract available.

PMID:
28278701
18.

Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group.

Grzasko N, Hajek R, Hus M, Chocholska S, Morawska M, Giannopoulos K, Czarnocki K, Druzd-Sitek A, Pienkowska-Grela B, Rygier J, Usnarska-Zubkiewicz L, Dytfeld D, Kubicki T, Jurczyszyn A, Korpysz M, Dmoszynska A.

Leuk Lymphoma. 2017 Sep;58(9):1-15. doi: 10.1080/10428194.2016.1272684. Epub 2017 Jan 16. Erratum in: Leuk Lymphoma. 2017 Oct;58(10):2518.

PMID:
28092996
19.

Expression of circulating miRNAs associated with lymphocyte differentiation and activation in CLL-another piece in the puzzle.

Filip AA, Grenda A, Popek S, Koczkodaj D, Michalak-Wojnowska M, Budzyński M, Wąsik-Szczepanek E, Zmorzyński S, Karczmarczyk A, Giannopoulos K.

Ann Hematol. 2017 Jan;96(1):33-50. doi: 10.1007/s00277-016-2840-6. Epub 2016 Oct 12.

20.

PD1/PD1L pathway, HLA-G and T regulatory cells as new markers of immunosuppression in cancers.

Własiuk P, Putowski M, Giannopoulos K.

Postepy Hig Med Dosw (Online). 2016 Oct 4;70(0):1044-1058. Review.

PMID:
27708209
21.

Comparative proteomic profiling of refractory/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy.

Dytfeld D, Luczak M, Wrobel T, Usnarska-Zubkiewicz L, Brzezniakiewicz K, Jamroziak K, Giannopoulos K, Przybylowicz-Chalecka A, Ratajczak B, Czerwinska-Rybak J, Nowicki A, Joks M, Czechowska E, Zawartko M, Szczepaniak T, Grzasko N, Morawska M, Bochenek M, Kubicki T, Morawska M, Tusznio K, Jakubowiak A, Komarnicki MA.

Oncotarget. 2016 Aug 30;7(35):56726-56736. doi: 10.18632/oncotarget.11059.

22.

Specific cytotoxic T-cell immune responses against autoantigens recognized by chronic lymphocytic leukaemia cells.

Zaleska J, Skorka K, Zajac M, Karczmarczyk A, Karp M, Tomczak W, Hus M, Wlasiuk P, Giannopoulos K.

Br J Haematol. 2016 Aug;174(4):582-90. doi: 10.1111/bjh.14098. Epub 2016 Apr 21.

PMID:
27097566
23.

Laccase purified from Cerrena unicolor exerts antitumor activity against leukemic cells.

Matuszewska A, Karp M, Jaszek M, Janusz G, Osińska-Jaroszuk M, Sulej J, Stefaniuk D, Tomczak W, Giannopoulos K.

Oncol Lett. 2016 Mar;11(3):2009-2018. Epub 2016 Feb 9.

24.

Association between increased levels of regulatory T cells and soluble human leukocyte antigen G with the prevalence of cancer in kidney transplant recipients.

Własiuk P, Steć A, Świder R, Durlik M, Giannopoulos K, Książek A.

Pol Arch Med Wewn. 2015;125(10):779-82. Epub 2015 Oct 8. No abstract available.

25.

Accumulation of CD5+CD19+ B lymphocytes expressing PD-1 and PD-1L in hypertrophied pharyngeal tonsils.

Wlasiuk P, Niedzielski A, Skorka K, Karczmarczyk A, Zaleska J, Zajac M, Putowski M, Pac-Kozuchowska E, Giannopoulos K.

Clin Exp Med. 2016 Nov;16(4):503-509. Epub 2015 Aug 29.

26.

Indirect induction of regulatory T cells accompanies immune responses during peptide vaccination of chronic lymphocytic leukaemia patients.

Skorka K, Zaleska J, Zajac M, Karczmarczyk A, Tomczak W, Wlasiuk P, Kowal M, Goetz M, Greiner J, Schmitt M, Giannopoulos K.

Br J Haematol. 2016 Jul;174(1):155-7. doi: 10.1111/bjh.13657. Epub 2015 Aug 25. No abstract available.

PMID:
26304747
27.

Expression of Programmed Death 1 Ligand in Different Compartments of Chronic Lymphocytic Leukemia.

Grzywnowicz M, Karczmarczyk A, Skorka K, Zajac M, Zaleska J, Chocholska S, Tomczak W, Giannopoulos K.

Acta Haematol. 2015;134(4):255-62.

28.

The Role of IL-17 and Th17 Lymphocytes in Autoimmune Diseases.

Tabarkiewicz J, Pogoda K, Karczmarczyk A, Pozarowski P, Giannopoulos K.

Arch Immunol Ther Exp (Warsz). 2015 Dec;63(6):435-49. doi: 10.1007/s00005-015-0344-z. Epub 2015 Jun 11. Review.

29.

Cytotoxic activity of valproic acid on primary chronic lymphocytic leukemia cells.

Karp M, Kosior K, Karczmarczyk A, Zając M, Zaleska J, Tomczak W, Chocholska S, Hus M, Dmoszyńska A, Giannopoulos K.

Adv Clin Exp Med. 2015 Jan-Feb;24(1):55-62. doi: 10.17219/acem/29264.

30.

Sorafenib improves rituximab and ofatumumab efficacy by decreasing the expression of complement regulatory proteins.

Dwojak M, Bobrowicz M, Bil J, Bojarczuk K, Pyrzynska B, Siernicka M, Malenda A, Lech-Maranda E, Tomczak W, Giannopoulos K, Golab J, Winiarska M.

Blood Cancer J. 2015 Apr 10;5:e300. doi: 10.1038/bcj.2015.27. No abstract available.

31.

The function of a novel immunophenotype candidate molecule PD-1 in chronic lymphocytic leukemia.

Grzywnowicz M, Karabon L, Karczmarczyk A, Zajac M, Skorka K, Zaleska J, Wlasiuk P, Chocholska S, Tomczak W, Bojarska-Junak A, Dmoszynska A, Frydecka I, Giannopoulos K.

Leuk Lymphoma. 2015;56(10):2908-13. doi: 10.3109/10428194.2015.1017820. Epub 2015 Mar 14.

PMID:
25682964
32.

Clinical and molecular genetic findings in autosomal dominant OPA3-related optic neuropathy.

Sergouniotis PI, Perveen R, Thiselton DL, Giannopoulos K, Sarros M, Davies JR, Biswas S, Ansons AM, Ashworth JL, Lloyd IC, Black GC, Votruba M.

Neurogenetics. 2015 Jan;16(1):69-75. doi: 10.1007/s10048-014-0416-y. Epub 2014 Aug 27.

PMID:
25159689
33.

Cereblon expression predicts clinical response in chronic lymphocytic leukemia treated with a thalidomide/fludarabine regimen.

Jamroziak K, Szemraj J, Robak T, Tukiendorf A, Giannopoulos K.

Leuk Lymphoma. 2015 Mar;56(3):808-10. doi: 10.3109/10428194.2014.933215. Epub 2014 Jul 17. No abstract available.

PMID:
24925210
34.

Thalidomide regulation of NF-κB proteins limits Tregs activity in chronic lymphocytic leukemia.

Skórka K, Bhattacharya N, Własiuk P, Kowal M, Mertens D, Dmoszyńska A, Giannopoulos K.

Adv Clin Exp Med. 2014 Jan-Feb;23(1):25-32.

35.

B-cell receptor pathway inhibitors affect CD20 levels and impair antitumor activity of anti-CD20 monoclonal antibodies.

Bojarczuk K, Siernicka M, Dwojak M, Bobrowicz M, Pyrzynska B, Gaj P, Karp M, Giannopoulos K, Efremov DG, Fauriat C, Golab J, Winiarska M.

Leukemia. 2014 May;28(5):1163-7. doi: 10.1038/leu.2014.12. Epub 2014 Jan 10. No abstract available.

PMID:
24492323
36.

Antigen stimulation in the development of chronic lymphocytic leukemia.

Karp M, Giannopoulos K.

Postepy Hig Med Dosw (Online). 2013 Dec 5;67:1204-13. Review.

37.

Clonal evolution in CLL patients as detected by FISH versus chromosome banding analysis, and its clinical significance.

Wawrzyniak E, Kotkowska A, Blonski JZ, Siemieniuk-Rys M, Ziolkowska E, Giannopoulos K, Robak T, Korycka-Wolowiec A.

Eur J Haematol. 2014 Feb;92(2):91-101. doi: 10.1111/ejh.12215. Epub 2013 Dec 2.

PMID:
24138550
38.

Micro magnetofluidics: droplet manipulation of double emulsions based on paramagnetic ionic liquids.

Misuk V, Mai A, Giannopoulos K, Alobaid F, Epple B, Loewe H.

Lab Chip. 2013 Dec 7;13(23):4542-8. doi: 10.1039/c3lc50897h.

PMID:
24108233
39.

Total expression of HLA-G and TLR-9 in chronic lymphocytic leukemia patients.

Własiuk P, Tomczak W, Zając M, Dmoszyńska A, Giannopoulos K.

Hum Immunol. 2013 Dec;74(12):1592-7. doi: 10.1016/j.humimm.2013.08.277. Epub 2013 Aug 29.

PMID:
23994589
40.

The VEGF receptor, neuropilin-1, represents a promising novel target for chronic lymphocytic leukemia patients.

Piechnik A, Dmoszynska A, Omiotek M, Mlak R, Kowal M, Stilgenbauer S, Bullinger L, Giannopoulos K.

Int J Cancer. 2013 Sep 15;133(6):1489-96. doi: 10.1002/ijc.28135. Epub 2013 Mar 29.

41.

Programmed death-1 and its ligand are novel immunotolerant molecules expressed on leukemic B cells in chronic lymphocytic leukemia.

Grzywnowicz M, Zaleska J, Mertens D, Tomczak W, Wlasiuk P, Kosior K, Piechnik A, Bojarska-Junak A, Dmoszynska A, Giannopoulos K.

PLoS One. 2012;7(4):e35178. doi: 10.1371/journal.pone.0035178. Epub 2012 Apr 19.

42.

Expression of soluble HLA-G in multiple myeloma patients and patients with renal failure.

Wlasiuk P, Stec A, Piechnik A, Kaminska W, Dmoszynska A, Ksiazek A, Giannopoulos K.

Leuk Res. 2012 Jul;36(7):881-3. doi: 10.1016/j.leukres.2012.02.015. Epub 2012 Mar 13.

PMID:
22421410
43.

The frequency of T regulatory cells modulates the survival of multiple myeloma patients: detailed characterisation of immune status in multiple myeloma.

Giannopoulos K, Kaminska W, Hus I, Dmoszynska A.

Br J Cancer. 2012 Jan 31;106(3):546-52. doi: 10.1038/bjc.2011.575. Epub 2012 Jan 5.

44.

Tyrosine kinase inhibitors in hematological malignancies.

Kosior K, Lewandowska-Grygiel M, Giannopoulos K.

Postepy Hig Med Dosw (Online). 2011 Dec 5;65:819-28. Review.

45.

Treating chronic lymphocytic leukemia with thalidomide and lenalidomide.

Giannopoulos K, Mertens D, Stilgenbauer S.

Expert Opin Pharmacother. 2011 Dec;12(18):2857-64. doi: 10.1517/14656566.2011.635644. Review.

PMID:
22098228
46.

Leukemic priming of resting NK cells is killer Ig-like receptor independent but requires CD15-mediated CD2 ligation and natural cytotoxicity receptors.

Sabry M, Tsirogianni M, Bakhsh IA, North J, Sivakumaran J, Giannopoulos K, Anderson R, Mackinnon S, Lowdell MW.

J Immunol. 2011 Dec 15;187(12):6227-34. doi: 10.4049/jimmunol.1101640. Epub 2011 Nov 14.

47.

Peptide vaccination induces profound changes in the immune system in patients with B-cell chronic lymphocytic leukemia.

Giannopoulos K, Własiuk P, Dmoszyńska A, Roliński J, Schmitt M.

Folia Histochem Cytobiol. 2011;49(1):161-7.

48.

Gene expression profiling in MDS and AML: potential and future avenues.

Theilgaard-Mönch K, Boultwood J, Ferrari S, Giannopoulos K, Hernandez-Rivas JM, Kohlmann A, Morgan M, Porse B, Tagliafico E, Zwaan CM, Wainscoat J, Van den Heuvel-Eibrink MM, Mills K, Bullinger L.

Leukemia. 2011 Jun;25(6):909-20. doi: 10.1038/leu.2011.48. Epub 2011 Mar 29. Review.

PMID:
21445077
49.

Effect of a fixed brimonidine-timolol combination on intraocular pressure after phacoemulsification.

Pharmakakis N, Giannopoulos K, Stasinos S, Makri OE, Georgakopoulos CD.

J Cataract Refract Surg. 2011 Feb;37(2):279-83. doi: 10.1016/j.jcrs.2010.08.046.

PMID:
21241910
50.

Definition of a target for immunotherapy and results of the first Peptide vaccination study in chronic lymphocytic leukemia.

Tabarkiewicz J, Giannopoulos K.

Transplant Proc. 2010 Oct;42(8):3293-6. doi: 10.1016/j.transproceed.2010.07.022. Review.

PMID:
20970674

Supplemental Content

Loading ...
Support Center